Downregulates IL-6, TNF-, and COX-2 to suppress excessive inflammatory response
These laboratory abnormalities may progress, may remain unchanged or may be transient with continuing therapy
ii) Moderate risk: Two criteria rated as unclear, or one criterion not met
The perimenopausal years occur after the reproductive years, but before menopause
Have certain eye diseases such as wet macular degeneration, diabetic retinopathy, or macular edema
It accelerates re-epithelialization, supports stem cell differentiation, and improves recovery in aged or damaged tissues through increased microvessel density and modulated inflammatory pathways (e.g., NF-B and MAPK)